New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
11:32 EDTILMN, SQNM, PKI, LHLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
News For LH;SQNM;ILMN;PKI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
14:22 EDTLHLabCorp price target raised to $130 from $113 at Craig-Hallum
Subscribe for More Information
November 24, 2014
08:32 EDTPKIPerkinElmer to acquire Perten Instruments for approximately $266M
Subscribe for More Information
November 21, 2014
08:48 EDTLHLabCorp completes acquisition of LipoScience
Subscribe for More Information
November 20, 2014
09:32 EDTLHLipoScience to host special shareholder meeting
Subscribe for More Information
November 19, 2014
07:09 EDTPKIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
06:10 EDTILMNIllumina, USAID and Broad Institute partner to combat ebola in West Africa
Illumina, the U.S. Agency for International Development and the Broad Institute of MIT and Harvard, have entered into a public-private partnership to help combat the Ebola epidemic in West Africa with aid for those on the ground who are fighting the spread of the virus. The partnership will train local and outbreak-deployed personnel to sequence viral genomes from the outbreak, and will extend surveillance operations, as well as equip facilities in West Africa with state-of-the-art genome sequencing technology.
November 18, 2014
07:20 EDTPKIEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 13, 2014
10:01 EDTLHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Hold from Buy at Argus... Adeptus Health (ADPT) downgraded to Hold from Buy at Deutsche Bank... American Woodmark (AMWD) downgraded to Neutral from Buy at Longbow... Avnet (AVT) downgraded to Sell from Neutral at Goldman... Baxano Surgical (BAXS) downgraded to Sell from Buy at Summer Street... Beazer Homes (BZH) downgraded to Neutral from Overweight at JPMorgan... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley... Centene (CNC) downgraded to Market Perform from Outperform at FBR Capital... Cherry Hill Mortgage (CHMI) downgraded to Equal Weight from Overweight at Barclays... Discover (DFS) downgraded to Hold from Buy at Deutsche Bank... Fleetmatics (FLTX) downgraded to Neutral from Buy at BofA/Merrill... Gazprom (OGZPY) downgraded to Neutral from Overweight at JPMorgan... Jabil Circuit (JBL) downgraded to Neutral from Buy at Goldman... LabCorp (LH) downgraded to Hold from Buy at Deutsche Bank... Laredo Petroleum (LPI) downgraded at BMO Capital... Macy's (M) downgraded to Market Perform from Outperform at Wells Fargo... Madison Square Garden (MSG) downgraded to Equal Weight from Overweight at Morgan Stanley... Marvell (MRVL) downgraded to Sell from Neutral at Goldman... Meritor (MTOR) downgraded to Neutral from Overweight at Piper Jaffray... Swedbank (SWDBY) downgraded to Underperform from Sector Perform at RBC Capital... TransGlobe (TGA) downgraded to Sector Perform from Outperform at Scotia Capital... UIL Holdings (UIL) downgraded to Hold from Buy at Argus... Verint Systems (VRNT) downgraded to Fair Value from Buy at CRT Capital... ZAIS Financial (ZFC) downgraded to Equal Weight from Overweight at Barclays.
06:16 EDTLHLabCorp downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded LabCorp (LH) to Hold saying revenue synergies from the Covance (CVD) acquisition are "hard to envision." The firm believes LabCorp is now less of a pure play in the Clinical Labs space and lowered its price target for shares to $115 from $120. Deutsche coupled the downgrade with an upgrade of peer Quest (DGX).
06:13 EDTLHQuest Diagnostics upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use